EPA Lipid Intervention and Atherosclerosis Prevention Study-ELIA Study
Phase 4
- Conditions
- stable coronary heart disease patients with dyslipidemia
- Registration Number
- JPRN-UMIN000002171
- Lead Sponsor
- Center for Clinical Research, Yamaguchi University Hospital
- Brief Summary
EPA may reduce oxidative stress and inhibit the progression of arterial stiffness more efficiently than statin-only therapy in patients with dyslipidemia and CAD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)myocardial infarction within 3 months 2)unstable angina 3)combined severe heart disease 4)post-cardiac intervention within 3 months 5)cerebrovascular disease within 3 months combined severe hepatic or renal disease 6)malignamcy 7)uncontrolled diabetes 9)secondary dyslipidemia 10)steroid-induced hyperlipidemia 11)familiar hypercholesterolemia 12)bleeding tendency 13)chronic atrial fibrillation 14)pregnancy or expected pregnancy 15)age 70 year-old and or over 16)peripheral artery diase (Fontane2 and more) 17)investigator-decided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method relationship among oxidative stress and lipid profile, and aortic stiffness and carotid atherosclerosis
- Secondary Outcome Measures
Name Time Method 1)relationship between cardiovascular event and oxidative stress 2)relationship between inflammatory marker and aortic stiffness 3)relationship between coronary risk factors and oxidative stress